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Abstract
The Karyopherin superfamily is a major class of soluble trans-
port receptors consisting of both import and export proteins.
The trafficking of proteins involved in transcription, cell signal-
ling and cell cycle regulation among other functions across
the nuclear membrane is essential for normal cellular function-
ing. However, in cancer cells, the altered expression or local-
ization of nuclear transporters as well as the disruption of
endogenous nuclear transport inhibitors are some ways in
which the Karyopherin proteins are dysregulated. The value of
nuclear transporters in the diagnosis, prognosis and treatment
of cancer is currently being elucidated with recent studies
highlighting their potential as biomarkers and therapeutic tar-
gets. VC 2016 IUBMB Life, 68(4):268–280, 2016
Keywords: Karyopherin/Importin; CRM1/Exportin; nuclear transport;
cancer; diagnostic/prognostic cancer biomarkers; therapeutic target
Introduction
Protein trafficking is fundamental to cellular function and cell
survival. Of the protein trafficking systems found in cells,
access into the nucleus through the nuclear pore complex
(NPC) is essential for the functioning of many proteins. Pro-
teins smaller than 20–40 kDa can passively diffuse through the
NPC while larger proteins require active facilitated transport
to gain access in or out of the nucleus.
Facilitated transport of numerous proteins is achieved via
the action of the Karyopherin proteins. The Karyopherin
superfamily consists of both the Karyopherin beta/Importin
beta family and the Karyopherin alpha/Importin alpha family
of adaptor proteins. The Karyopherin beta family forms the
major class of soluble transport receptors. Its members inter-
act with and import and/or export cargo proteins and certain
RNAs across the nuclear envelope. Thus far there have been
20 genes encoding Karyopherin beta family members identi-
fied in the human genome including 10 proteins involved in
nuclear import, seven proteins involved in nuclear export,
two bidirectional transporters and one transporter that
remains uncharacterised (Table 1) (40). The Karyopherin
alpha family of adaptor proteins bind the nuclear localisation
signal (NLS) of cargo proteins and link them to the Karyo-
pherin beta transport protein, hence playing the role of an
adaptor. Seven Karyopherin alpha isoforms are currently
characterised, which are grouped into three subfamilies: A1,
A2 and A3. The A1 subfamily comprises Karyopherin A2 and
Karyopherin A7, the A2 subfamily includes Karyopherin A3
and Karyopherin A4 and, finally, the A3 subfamily consists of
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Karyopherin A1, Karyopherin A5 and Karyopherin A6
(Table 1) (41).
The classical nuclear import pathway involves a Karyo-
pherin alpha isoform recognising and binding a cargo contain-
ing a classical nuclear localisation signal (cNLS), which is then
bound by Karyopherin beta 1 (KPNB1). This trimeric complex
is then shuttled through the NPC. An alternative path of
nuclear import involves the cargo protein bypassing the need
for an adaptor and binding KPNB1 directly. Cargo proteins
such as parathyroid hormone-related protein (PTHrP) and ste-
rol regulatory-related protein (SREPB2) use this mode of
nuclear import (2). Passage through the NPC is mediated by
the interactions between Phe-Gly repeat-containing nucleopor-
ins of the NPC and KPNB1. Upon arrival in the nucleus, a key
event is the binding of RanGTP to the KPN/cargo complex,
which promotes dissociation of the import complex, allowing
the cargo to remain in the nucleus and the transport proteins
to be recycled (42,43). The nuclear export protein, CSE1L, is
responsible for recycling the Karyopherin alphas back into the
cytoplasm. XPO1, the most well-characterised export protein,
binds cargoes containing a leucine-rich nuclear export signal
(NES). RanGTP stabilizes the XPO1-bound NES–cargo complex
that can then pass through the NPC towards the cytoplasm.
When in the cytoplasm, the hydrolysis of RanGTP to RanGDP
allows the dissociation of the export protein and the cargo
(Fig. 1) (44).
Although the best described role of the Karyopherin pro-
teins is the nuclear import and export of cargo proteins, they
also play an important role in mitosis and other cell cycle-
regulated functions including regulating the assembly of the
NPC and nuclear membrane at mitotic exit as well as DNA
replication in S-phase (45,46). During normal cellular homeo-
stasis, the nuclear transport system is regulated through vari-
ous mechanisms including signal transduction, cell cycle,
immune response, development and stress (42). Dysregulation
of nuclear transport has been associated with carcinogenesis
and poor prognosis in a multitude of cancers. This review
aims to discuss recent work revolving around the role of key
nuclear transport receptors in cancer. It will cover the dysre-
gulation of nuclear transport pathways and focus on the poten-
tial of targeting these transporters in the diagnosis, prognosis
and treatment of cancer.
Proposed dysregulation of nuclear–cytoplasmic transport of cargo proteins in cancer cells in comparison to normal. (a) In nor-
mal cells protein cargo containing a nuclear localisation signal (NLS-cargo) is recognised and bound by a Karyopherin alpha
(A) transport protein after which this complex is bound by Karyopherin beta 1 (KPNB1) and allowed passage through the
nuclear pore complex (NPC). Upon association with RanGTP the cargo protein dissociates and the nuclear transport proteins
are recycled back into the cytoplasm. Recycling of the Karyopherin alpha protein occurs through binding to CSE1L and in asso-
ciation with RanGTP is transported back through the NPC into the cytoplasm. Nuclear protein cargo containing a nuclear export
signal (NES-Cargo) is recognised and bound by XPO1 where again in association with RanGTP is transported through the NPC
into the cytoplasm. (b) In cancer cells it is proposed that the overexpression of nuclear transporters (green 1), including
KPNB1, XPO1 and CSE1L leads to an increased rate of transport through the NPC. As a result their respective cargoes poten-
tially accumulate in the cytoplasm or nucleus. Nuclear transporters can also be mislocalized (red 2) rendering them non-
functional and inhibiting transport through the NPC which causes accumulation of cargo proteins in their compartment of ori-
gin. Both overexpression of nuclear transporters and their mislocalization have been seen in cancer and associated with
increased proliferation and increased survival.
FIG 1
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Dysregulation of Nuclear Transport
in Cancer
The Karyopherin superfamily of proteins play a fundamental
and indispensable role in normal cell physiology by providing
the means of trafficking between the cytoplasm and the
nucleus as well as in other cellular processes such as mitosis.
As intracellular localization of many proteins as well as the
nuclear transporters themselves has an impact on their activ-
ity status and/or function, the correct spatial arrangement of
proteins at the correct time is critical. It is therefore no sur-
prise that impaired regulation of nuclear–cytoplasmic trans-
port associates with pathogenesis. A well-researched area is
the association of nuclear transport dysregulation and cancer,
which most commonly leads to the mislocalization of cancer-
associated cargo proteins (Fig. 1). For example, the nuclear
accumulation of the DNA repair protein, NBS1, has been
shown to correlate with gastric cancer progression, while the
cytoplasmic accumulation of Wilms’ tumour protein, Wt1, was
observed more frequently in malignant tissues than normal
(11,47). There are many junctions in the nuclear transport
pathways at which dysregulation can occur; here we discuss
mechanisms that are more frequently observed and are known
to be linked to cancer. These include: (i) the altered expression
of the nuclear transporters, (ii) altered localization of nuclear
transporters, (iii) the disruption of endogenous nuclear trans-
port inhibitors and (iv) the mechanistic implications of nuclear
transporters in mitotic division and genetic instability.
Altered Expression of the Nuclear Transporters
The elevated expression of the Karyopherin proteins associates
with the global dysregulation of protein transport and this has
been observed in various types of cancer. Amongst all mem-
bers of the Karyopherin family, XPO1, KPNB1, KPNA2 and
CSE1L are the most frequently reported to be overexpressed in
cancer (Table 1). Kuusisto et al. found that the increased
expression of these Karyopherin proteins in transformed cells
correlates with enhanced nuclear import and export efficien-
cies in transformed cells (48). The increased expression and
thus transportation across the nuclear membrane is possibly a
mechanism devised by cancer cells to cope with the increased
metabolic and proliferative demands. The increased expres-
sion of import proteins, in particular, might allow for
increased nuclear entry of proteins that have oncogenic
tumour-promoting functions, for example, ERK1/2, c-Myc and
E2F1 (49–51).
Whilst the link between Karyopherin overexpression and
cancer has been the subject of numerous studies, few
researchers have addressed the underlying mechanism leading
to their overexpression. Using molecular and bioinformatics
approaches, van der Watt et al. showed that the overexpres-
sion of both KPNB1 and KPNA2 is primarily due to dysregu-
lated E2F/Rb activity in cancer cells. The constitutive activa-
tion of E2F in, e.g., cervical cancer cells was found to
associate with increased expression of both KPNB1 and
KPNA2 (7). It is well known that HPV infection in cervical can-
cer results in E2F dysregulation and thus elevated KPNB1 and
KPNA2 in this cancer. The E2F/Rb pathway is disrupted in a
remarkably high proportion of human cancers through other
mechanisms leading to the same overexpression phenotype
(52). Interestingly, Kuusisto et al. showed that the extent of
overexpression of KPNB1 correlates with disease state in the
MCF10 human breast tumour progression system, suggesting
that its overexpression not only correlates with E2F dysregula-
tion but can vary according to tumour progression state (5).
Other mechanisms for altered Karyopherin expression have
been reported. A recent study showed elevated KPNA2 expres-
sion resulting from decreased expression of microRNA-26b in
epithelial ovarian carcinoma. MicroRNA-26b directly targets
KPNA2 by repressing its translation and thus reduced
microRNA-26b resulted in elevated KPNA2 expression (53).
Quan et al. used bioinformatic approaches to predict tran-
scription factors that bind the promoter regions of Karyo-
pherin beta genes and identified Sp1, NRF-2, HEN-1, RREB-1
and NFY as potential regulators of Karyopherin beta expres-
sion (54). In line with this, van der Watt et al. found that
increased NFY and Sp1 expression in cervical cancer and
transformed are both potential contributors to XPO1 overex-
pression in these cells (7). Interestingly, Kahle et al. found that
NFY-A is imported into the nucleus by KPNB1 where it acts to
transcribe its downstream targets (55). This finding could
explain why the elevated expression of KPNB1 has been
observed concomitant with elevated XPO1 in cervical and gas-
tric cancer (3, 4, 22). van der Watt et al. also showed that
under DNA damage conditions the elevated p53 level plays a
repressive role in the transcription of the xpo1 gene (3). It is
not surprising then that XPO1 overexpression is commonly
observed in cancer as p53 is often expressed at low levels or
contains mutations in many cancers (56). Interestingly, XPO1
has also been shown to be involved in p53 nuclear export (3),
suggesting that a possible feedback regulatory mechanism
may exist. Under DNA damage conditions p53 expression
increases and enters the nucleus, thereby repressing XPO1
expression. The reduced XPO1 expression will in turn enhance
p53 retention in the nucleus further repressing XPO1 expres-
sion. In p53-deficient or -mutant cells the repression of XPO1
expression is relieved, likely leading to XPO1 overexpression.
The CSE1L protein, also a member of the Karyopherin
family involved in recycling the KPNA adaptors into the cyto-
plasm, is another member commonly reported to be overex-
pressed in cancer including bladder, leukaemia, breast, colon,
ovarian and non-Hodgkin’s lymphoma (28, 31, 34, 35). Its
overexpression has been attributed to gene amplification (31).
More recent work by Winkler et al. demonstrated a repressive
role of p53 in CSE1L and KPNA2 transcription in hepatocellu-
lar carcinoma mediated through p21 (57). As p53 loss-of-
function is a frequent occurrence in cancer it is not surprising
to observe overexpression of CSE1L in cancer.
The altered expression of nuclear transporters associated
with cancer more often involves elevated expression; however,
IUBMB LIFE
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downregulation of nuclear transporters has also been linked to
cancer. Exportin 4 (XPO4) is an example although the exact
underlying mechanism driving its downregulation is still
unknown (39).
Altered Localization of Nuclear Transporters
The ability of nuclear transporters to efficiently execute their
functions depends on their ability to interact correctly with
other members of the transport cycle. A truncated KPNA lack-
ing part of the cargo-NLS-binding domain has also shown fail-
ure to interact with and transport p53 into the nucleus in
breast cancer cells. Despite the KPNB1-binding domain
remaining intact in the mutant KPNA, it was localized predom-
inantly in the cytoplasm and perinuclear region as opposed to
the even distribution observed in wild-type KPNA (58). This
suggests that cargo recognition and binding by KPNA is a pre-
requisite for nuclear entry, and that pairing with KPNB1 alone
is not sufficient. A similar observation was made by Melo
et al., where an inactivating mutation in Exportin 5 (XPO5)
found in a subset of human tumours rendered it unable to
export itself as well as its precursor microRNA cargoes out of
the nucleus (36). As a result, the pre-microRNA processing
efficiency was decreased leading to defects in microRNA pro-
duction. Ultimately, failure to generate mature microRNA
leads to the impairment of the post-translational regulation of
target genes and altered expression profile.
Post-translational modification can also regulate protein
localization, which is well demonstrated by the CSE1L protein.
CSE1L is involved in more than one function inside the cell, but
its role in nuclear transport is specifically carried out when
localized to the nucleus (59). Its localization is phosphorylation-
dependent, while AKT-mediated phosphorylation is required for
its nuclear localization in ovarian cancer; MEK-1-mediated
phosphorylation retains it in the cytoplasm (60,61). Further-
more, siRNA-mediated inhibition of CSE1L expression in ovarian
cancer cells which exhibited predominant nuclear localization of
CSE1L showed increased sensitivity to cisplatin treatment com-
pared to breast and colon cancers which showed predominant
cytoplasmic localization (60). This suggests that the nuclear
CSE1L plays an oncogenic role and could contribute to the
resistance against cytotoxic agents. The aberrant function of the
upstream kinases can thus result in the incorrect localization of
CSE1L and resultant pathogenesis.
Disruption of Endogenous Nuclear
Transport Inhibitors
Cells also use endogenous nuclear transport inhibitors to regu-
late nuclear trafficking. The two most well-known endogenous
inhibitors are Complement Component 3 (CC3/TIP30) and
Aplasia Ras Homolog Member 1 (ARH1/NOEY2). Both proteins
were found to have reduced expression or absence in a wide
range of cancers. Knockdown studies concluded that these
proteins function to suppress the cancer phenotype, while res-
toration of their expression was unfavourable to cancer devel-
opment. Their ability to negatively regulate nuclear transport
was only recognised about a decade later (62,63). Both pro-
teins have been reported to interfere with nuclear import by
physically interacting with members of the Karyopherin fam-
ily. Binding of CC3 to the Karyopherins was RanGTP-
independent and also associated with nucleoporins in vivo.
Alternatively, ARH1 is thought to interact with Karyopherins
through the NLS domain, thereby preventing NLS-cargo bind-
ing, and also competed with the binding of Karyopherin to Ran
(64). Both inhibitors have the ability to prevent nuclear trans-
location of NLS-cargoes while CC3 was also able to prevent
transport of M9 signal-bearing cargoes (62).The alleviation on
nuclear transport and the subsequent altered cellular localiza-
tion of cargo proteins has several advantages in tumour devel-
opment and survival.
Mechanistic Implications of Nuclear Transporters in
Mitotic Division and Genetic Instability
When nucleo-cytoplasmic transport ceases, virtually all trans-
port factors take on new roles in mitosis, acting in the func-
tional organisation of the mitotic spindle and in the reconstitu-
tion of the interphase nucleus at mitotic exit. Modelling studies
have indicated that subtle dysregulation of the expression of
transport factors readily affects mitotic division and can cause
significant abnormalities in chromosome segregation, whereas
nucleo-cytoplasmic transport is a more robust process (65,66).
Dysregulation of nuclear transport factors can therefore cause
the onset of genetic instability, a cancer hallmark (Fig. 2).
The role of KPNB1 as a regulator of spindle formation and
function is well described. KPNB1 generally acts by preventing
the premature localisation or activity of spindle regulatory fac-
tors (67). Factors, with spindle assembly functions, regulated
by KPNB1 include: the spindle pole-organizing protein NuMA
Role and implications of nuclear transporters in mito-
sis. Under normal conditions upon cessation of
nuclear transport, nuclear transport factors take on
new roles in mitosis. They contribute to the stabiliza-
tion of mitotic factors and regulated mitotic division.
Dysregulation of the expression of nuclear transport
factors has been shown to contribute to the altered
localization of key spindle regulatory factors that
associate with the onset of genetic instability, which
is considered one of the hallmarks of cancer.
FIG 2
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(68), the microtubule-regulatory protein HURP (69), Rae1/
Nup98 (70), a regulator of the Aurora-A kinase maskin (71)
and APC (72), among others. KPNB1’s physical association and
regulation of the Adenomatous polyposis coli (Apc) oncogene,
itself a microtubule-promoting and mitotic spindle-associated
factor, may be of particular relevance to the onset of colon
cancer (72). A novel function through which KPNB1 can glob-
ally regulate the mitotic apparatus has recently emerged and
concerns its ability to regulate, in concert with the APC/C
ubiquitin ligase, the stability of mitotic spindle regulatory
factors (73).
Transportin 1 (TNPO1) has documented effects on the
mitotic apparatus and on post-mitotic reorganization of the
interphase nucleus, a critical process that is evidently crucial
for resuming transcription and replication via the cell cycle
(74,75). Disruption of this process by altered TNPO1 function
will also affect the genetic identity of the newly formed daugh-
ter cells after mitosis.
The CSE1L protein has predominant roles in the regulation
of apoptosis, as recalled above, most probably mediated by the
mislocalization of Karyopherin alpha members. It also has the
ability to associate with the mitotic apparatus; altered activity
of CSE1L can confer resistance to taxol but not to other che-
motherapeutic drugs (76). This effect is mediated through Mek
proteins, and it is particularly interesting in the light of design-
ing new potential therapeutics (76,77).
Karyopherin alpha family members, although difficult to
discuss collectively, share a common functional feature that
their downregulation induces substantial levels of apoptosis
(78). They contribute to mitotic control by interacting with key
spindle regulatory factors such as TPX2 (79). In addition, kar-
yopherin alpha 3 has a global role in mitosis. It interacts spe-
cifically with RCC1, the guanine exchange factor for Ran, and
this interaction is inhibited by mitotic phosphorylation
(78,80,81). This inhibition results in an increased concentra-
tion of free RCC1 and hence increased RanGTP production in
mitosis.
The nuclear export protein, XPO1, has well-defined mitotic
effects exerted at various levels of mitosis. These include the
mitotic spindle (82); kinetochores, stabilizing microtubule/
kinetochore interactions essential for chromosome segregation
(83) and centrosomes, preventing chromosome reduplication
that constitutes a major threat to genome stability (84,85).
These effects are mediated through several mitotic targets that
contain NES sequences. The interplay between XPO1 and
mitotic cyclin B is interesting to note. XPO1 contributes to
cyclin B localization and in turn cyclin B phosphorylates XPO1
to finely regulate its mitotic functions (86). It has also been
reported that XPO1’s interaction with survivin is important to
target the chromosomal passenger protein to kinetochores
(87).
Nuclear transport plays a critical role in the functioning of
many cellular processes. Because of this, cells have developed
elegant systems to tightly control the nuclear transport proc-
esses. Unfortunately, within each junction in the regulatory
pathway lies an opportunity for errors to occur, and indeed
many of these alterations have been associated with cancer.
Role of Nuclear Transporters in the
Diagnosis of Cancer
Late diagnosis of cancer is a major contributing factor to poor
patient outcome. Often, by the time patients present at clinics,
the cancer has already progressed to later stages and the
chances of the primary tumour having already metastasised
are relatively high. This highlights a need for effective tools for
the early detection of cancer. The ideal biomarker would be
unique to cancer and present in easily obtainable patient sam-
ples such as serum or urine. Nuclear transporters have
already been shown to be upregulated at the protein level in
many cancer tissues but few studies recognise these proteins
as potential diagnostic biomarkers. Wang et al. investigated
potential biomarker targets that were both significantly upreg-
ulated in lung cancer tissues and secreted/released from lung
cancer cells. They achieved this by integrating two lung adeno-
carcinoma cell line secretome datasets with one adenocarci-
noma microarray dataset. Using this strategy they identified
KPNA2 as a potential diagnostic biomarker for adenocarci-
noma. Elevated KPNA2 serum levels were confirmed in a
cohort of non-small-cell lung carcinoma patients (n5126) in
comparison to healthy individuals (n564) (17). Similar to
what was observed in lung cancer patients, KPNA2 levels in
serum were also significantly upregulated in oesophageal
squamous cell carcinoma patients (n586) versus healthy con-
trols (n560) validating the potential of KPNA2 as a diagnostic
biomarker (88). KPNA2 has also been identified as a potential
diagnostic biomarker that can differentiate between grades of
astrocytoma. This, however, still requires immunohistochemi-
cal validation. The conventional criteria for differentiating
between WHO grade II and III astrocytomas is particularly dif-
ficult to define. Gousias et al. found that patients diagnosed
with WHO grade II astrocytoma showed little/no nuclear
KPNA2 immunostaining, whereas half of the patients diag-
nosed with anaplastic astrocytoma (WHO grade III) showed
5% KPNA2 staining in the nucleus (89).
The nuclear transporter, CSE1L, has also shown diagnostic
potential in bladder cancer and metastatic colorectal cancer
(29, 33). It is upregulated in bladder cancer and has been
found to be secreted into the urine of these patients while it is
not detected in the urine of healthy individuals (29). CSE1L has
also been found to be secreted into the sera of patients with
metastatic colorectal cancer (33). Thus far, no data have been
published regarding the serum levels of other nuclear trans-
port proteins in cancer. As previously mentioned, other mem-
bers of the Karyopherin superfamily such as KPNB1 and XPO1
have also been shown to be upregulated in various cancers. It
is thus possible that these proteins might also be secreted
from cancer cells and have potential as diagnostic markers.
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Nuclear Transporters as Prognostic
Markers
A study by van der Watt et al. found that KPNB1, KPNA2 and
XPO1 are all upregulated in cervical cancer patient samples in
comparison to normal tissue. KPNB1 and XPO1 but not KPNA2
were found to be essential for the survival of cervical cancer
cells. The nuclear importer, KPNB1, and exporter, XPO1, both
show promise as a cancer biomarker but have not as yet been
correlated to patient prognosis in cervical cancer (3). More
recently, Zhu et al. found that KPNB1 was also upregulated in
gastric cancer patient tissue and cells in comparison to their
normal counterparts. Interestingly, Zhou et al. found XPO1
protein levels to be significantly upregulated in gastric cancer
patient tissues as well, indicating that both import and export
machinery is upregulated in gastric cancer. The upregulation
of KPNB1 correlated positively with Ki-67 immunostaining,
infiltration depth and tumour grade but not TNM stage and
lymph node metastasis. On the other hand, overexpression of
XPO1 positively correlated with TNM stage as well as metasta-
sis. Both increased KPNB1 and XPO1 expression have been
identified as independent prognostic factors to predict gastric
cancer patient survival (4, 22).
XPO1 has also been identified as a suitable independent
prognostic marker in ovarian cancer, pancreatic cancer, osteo-
sarcoma, brain cancer and acute myeloid leukaemia (10, 23–
26, 90). Studies on pancreatic cancer as well as osteosarcoma
revealed XPO1 overexpression to be associated with increased
tumour size as well as histological grade in osteosarcoma but
not pancreatic cancer. For both pancreatic cancer and osteo-
sarcoma there is evidence suggesting that increased XPO1
expression is an indicator of reduced overall and progression-
free survival (24,25). In contrast, decreased expression of the
nuclear export protein, XPO4, was associated with poor overall
survival in patients with liver cancer suggesting XPO4 has
tumour suppressor properties (39,91). Although expression
levels of nuclear transporters often enhances their prognostic
value, in some cases so does their localisation within the cell.
While the localisation of XPO1 between the nucleus and the
cytoplasm showed no significant differences among gastric
cancer samples, the cellular localisation of XPO1 in ovarian
cancer has been correlated with different aspects of cancer
progression (22). Enhanced cytoplasmic XPO1 has been associ-
ated with advanced ovarian tumour stage, poor differentiation
and higher mitotic rate. Nuclear XPO1 levels have been associ-
ated with enhanced Cox-2 expression leading to poor overall
patient survival (23). Nuclear XPO1 has also been correlated
with pathological stage in gliomas (90). XPO1 localisation is
also altered during oesophageal tumourigenesis, where it
shifts from predominantly nuclear in normal tissue to nuclear
and cytoplasmic in cancer tissue. This appears to occur in the
early stages of disease progression (27).
The nuclear export protein, CSE1L, has been reported to
have prognostic potential in bladder, liver and ovarian cancers
(30, 32, (34)). Chang et al. found urothelial carcinoma patient
samples to have differing cytoplasm and nuclear CSE1L stain-
ing. While cytoplasmic CSE1L staining showed no correlation
to clinical manifestations, nuclear CSE1L closely correlated
with poor overall survival (30). In liver cancer, CSE1L was
found to be upregulated particularly in the cytoplasm of cells
in comparison to normal tissue, but the association to patient
outcome was not further investigated (32).
The value of nuclear transporters such as KPNB1, XPO1
and CSE1L as prognostic tools is still under investigation and
data supporting this are only available for a select few can-
cers. In contrast, KPNA2 has been well established as a prog-
nostic marker in various cancers including: breast cancer,
brain cancer, gastric cancer, prostate cancer, ovarian cancer,
bladder cancer, liver cancer, melanoma, lung cancer and
oesophageal cancer (8–11,14,15,92,93). Dahl et al.’s research
in breast cancer was the first to identify KPNA2 as a prognos-
tic marker (94). Since then high nuclear KPNA2 expression
has been linked to poor patient outcome. Numerous studies
have shown that KPNA2 expression correlates with overall
and progression-free survival in patients and established
KPNA2 as an independent prognostic marker when compared
to other clinical data (10, (11,13–15,89,93,95,96)). Interest-
ingly, KPNA2 expression also predicted the chances of metas-
tasis as well as histological grade and clinical stage of
tumours. High KPNA2 expression in non-invasive bladder can-
cer increased the risk of progression to a more invasive
form (13).
Some malignancies have a high recurrence rate following
therapeutic or surgical intervention and it is important to iden-
tify risk factors in these patients that might predict recurrence.
KPNA2 expression has been identified as a marker of both
early and more frequent recurrence in liver cancer while it is
also a marker of PSA recurrence in prostate cancer (9,97,98).
In meningioma, elevated KPNA2 and XPO1 expression was
observed in recurrent tumours in comparison to primary
tumours and this correlated with increased recurrence
rates (10).
The evidence presented here highlights that KPNA2 serves
as a valuable prognostic marker throughout the progression of
cancer from early-stage recurrence to chances of metastasis,
as well as overall survival. While there is evidence that
KPNB1, XPO1, CSE1L and XPO4 have shown potential as prog-
nostic markers, this requires further investigation and valida-
tion. Evidence from the study by Gousias et al., which shows
KPNA2 expression levels correlating with XPO1 expression lev-
els in meningioma, suggests that other nuclear transporters
may too have prognostic value in cancer (10).
Targeting Nuclear Transporters
as Cancer Therapeutics
The upregulation of nuclear transporters and their association
with poor prognosis in cancer highlights their potential as
therapeutic targets. Challenges may arise though when
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targeting cellular machinery that is active in both normal and
cancer cells. However, studies have shown that cancer cells
are more sensitive to nuclear transport inhibition than non-
cancer cells which remain viable (3, (5,99)). Specific knock-
down using siRNA for nuclear import proteins, KPNB1 and
KPNA2, and export proteins, XPO1 and CSE1L, in cancer cells
frequently results in reduced proliferation and increased apo-
ptosis (50,57,78,96,98,100–102). This suggests that cancer
cells may have an enhanced dependence on nuclear transport-
ers for their increased proliferative and metabolic demands
(referred to as tumour cell “addiction”).
Targeting Nuclear Export via XPO1
Among the Karyopherin family members, the nuclear
exporter, XPO1, has so far been the most successful chemo-
therapeutic target already being tested in clinical trials (Table
2). Several natural products were first described as inhibitors
of XPO1 with Leptomycin B being the most potent. Unfortu-
nately, Leptomycin B showed severe cytotoxic effects in phase
I clinical trials and was no longer pursued for use in patients.
Following that several Leptomycin B derivatives such as
Anguinomycin and Kos-2464 have been synthesized in an
attempt to reduce the cytotoxity while retaining the ability to
inhibit nuclear export via XPO1, but have as yet not entered
clinical trials. A recent review by Ishizawa et al. outlines the
history of XPO1 as a chemotherapeutic target in more detail
(21). In 2012 the SINE (selective inhibitors of nuclear export)
series of drugs were discovered through an in silico molecular
modelling strategy and synthesized by Karyopharm Therapeu-
tics (Karyopharm Therapeutics, Boston, MA) (110). These com-
pounds are water-soluble and irreversibly modify a cysteine
(Cys528) in the NES-binding groove of XPO1, thereby inhibiting
the function of the protein. KPT-185 is the most potent of the
series and is most commonly studied in vitro; however, KPT-
330/Selinexor, while nearly as potent, has more acceptable
pharmacokinetics and has shown promise in phase I and II
clinical trials in both haematological and solid tumours (111).
More recently, combination treatment strategies using
XPO1 inhibitors and currently available chemotherapeutic
agents have proven to be effective in enhancing the treatment
of cancer. Nuclear export inhibitors alone, while effective in
causing cell death in vitro, in animal models these inhibitors
while inhibiting tumour growth were less often likely to elimi-
nate existing tumours. The combination therapy is thought to
use the XPO1 inhibitor to sensitise cancer cells to chemothera-
peutic agents. A review by Turner et al. extensively discusses
Nuclear transport inhibitorsa
Nuclear transporters Inhibitor Nature of the compound Experimental status
KPNB1 cSN50.1 (103) Peptide Cell culture
KPNA/B1 Ivermectin (104) Antibiotic
cSN50.1 (103) Peptide Cell culture
Bimax1 (105) Peptide Cell culture
Bimax2 (105) Peptide Cell culture
Karystatin 1A (106) Small molecule Cell culture
Importazole (107) Small molecule Cell culture
TNPO1 M9M (108) Peptide Xenopus model
XPO1 Leptomycin B (109) Antibiotic Phase I clinical trials (discontinued)
Ratjadone analogs (21) Antibiotic Cell culture
Anguinomycin (21) Antibiotic Cell culture
Goniothalamin (21) Organic molecule Cell culture
Kos-2464 (21) Small molecule Xenograft mouse model
N-azolylacrylate analogs (21) Small molecule HIV model
CBS9106 (21) Small molecule Xenograft mouse model
SINE series (110) Small molecule Phase I–II clinical trials
aAs published until December 2015.
TABLE 2
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a range of studies providing evidence for the efficacy of XPO1
inhbitors in combination with alkylating agents, anthracy-
clines, BRAF inhibitors, platinum drugs, protease inhibitors
and tyrosine-kinase inhibitors against both haematological and
solid tumours (112). SINE compounds, KPT-185, KPT-249 and
KPT-330, were able to sensitize myeloma cells to doxorubicin,
bortezomib and carfilzomib and phase I/II clinical are cur-
rently underway (112,113). A combination therapy using KPT-
330 and gemcitabine has also been found to synergistically
enhance cell death in vitro and in vivo in pancreatic cancer
(114).
Targeting Nuclear Import via KPNB1 and KPNA
The field of nuclear import inhibitors, while not as advanced
as that of nuclear export inhibitors at present, is growing
(Table 2). Most commonly, KPNB1 and the KPNA isoforms
work together to transport cargoes into the nucleus, although
KPNB1 can also transport cargo independently. Therefore, tar-
geting KPNB1 may have a broader spectrum of import inhibi-
tion while targeting a single KPNA isoform would considerably
increase specificity. Pioneering work in the search for Karyo-
pherin alpha/beta 1 inhibitors was started by Lin et al. in
1995. They, among others, found that a cell-permeable peptide
containing the NLS of the NFjB p50 subunit was able to inhibit
the nuclear import of transcription factors containing a NLS,
such as NFjB, NFAT, AP-1 and STAT1 (115,116). The peptide
became better known as cSN50.1 and more recently has been
found to target both SREBP/KPNB1- and KPNA/NLS-cargo-
mediated import through two separate mechanisms. The inhi-
bition of SREBP/KPNB1-mediated import is thought to be
through the binding of the peptide’s SSHR motif with KPNB1.
The peptide is also able to bind all KPNA isoforms, except
KPNA6, with the highest affinity for KPNA1 and in that way
plays a role in the import inhibition of transcription factors
containing a NLS (103). Kosugi et al. also used peptide inhibi-
tor design to target the KPNA/B1 import pathway which
yielded two high-affinity peptides namely; Bimax1 and Bimax2.
They were found to specifically target the KPNA-mediated
import pathway and had no effect of KPNB1-only mediated
import although they showed no specificity for Karyopherin
alpha isoforms in mammalian cells (105). Unfortunately, the
chemotherapeutic ability of these import inhibitors remains
unknown. A peptide, M9M, has also been designed to inhibit
nuclear import but rather by targeting TNPO1 which recog-
nises a PY-NLS (108). M9M was used to elucidate the role of
TNPO1 in mitosis but its role in cancer has not been explored
(75). An antiparasitic antibiotic, Ivermectin, already on the
market, has also been found to bind non-specifically to
KPNB1/KPNA preventing binding to the cargo proteins (104).
Although Ivermectin has been shown to have anticancer
effects this seems to be through a mechanism of action unre-
lated to nuclear import inhibition (117).
Karyostatin 1A was the first small-molecule inhibitor of
KPNB1-mediated nuclear import to be described. Its mecha-
nism of action is thought to be through blocking the binding of
RanGTP to KPNB1 disrupting the KPNA/B1 import pathway
(106). The potential of this compound including its anticancer
effect has not been explored to date. Another small-molecule
inhibitor of nuclear import, Importazole, developed by Soder-
holm et al., was found to interfere with the interaction
between RanGTP and KPNB1 and specifically disrupts KPNB1-
mediated import without affecting Transportin or XPO1-
mediated transport (107). Importazole successfully inhibited
NFjB p65 nuclear localisation in myeloma cells and induced
apoptosis without affecting normal plasma cells, showing
promise as an anticancer compound (118). Although no studies
have been published using nuclear import inhibitors in combi-
nation with currently available chemotherapeutic agents it
may be an area of interest following the potential success of
combination therapies with nuclear export inhibitors.
Although other members of the Karyopherin family, such
as CSE1L, show promise as cancer therapeutic targets, no
inhibitors are available for any of the other transport proteins
as yet. The targeting of other nuclear transport proteins that
have a more limited selection of cargoes may have value as
anticancer strategies. For this to occur, their association with
cancer requires further investigation.
Conclusions and Perspectives
Nuclear transport proteins play an essential role in cellular
functioning. Hence, the increased reliance, of transformed and
cancer cells, on the nuclear transport proteins for their
increased metabolic demands warrants their usefulness as
chemotherapeutic targets. More recently, the potential of
nuclear transporters as cancer biomarkers has been investi-
gated. For example, the secretion of certain Karyopherin pro-
teins into the urine or serum of cancer patients shows diag-
nostic potential, while the differential expression of
Karyopherin proteins in cancer tissue in comparison to normal
tissue suggests that these proteins have potential as prognostic
markers as well. Further research is required to elucidate the
clinical potential of nuclear transport proteins as diagnostic,
prognostic and therapeutic targets.
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